Healix Announces First Real-World Study of Immune Globulin Subcutaneous 16.5% (Cutaquig®) Featured in the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
SUGAR LAND, TX – (May 7, 2020)
Healix Infusion Therapy is pleased to announce that its collaborative research study regarding Immune Globulin Subcutaneous 16.5% (Cutaquig®) is now accessible in the AAAAI Annual Meeting Virtual Poster Hall.
The study by authors Richard Herrscher, MD, Jeffrey Langford, MD, et al, entitled “Real-World Evaluation of Efficacy and Tolerability of Immune Globulin Subcutaneous 16.5% in the Treatment of Patients with Primary Immunodeficiency” is featured under Clinical Immunology in the AAAAI virtual poster hall, Poster #101. This first real-world data presentation of Cutaquig® was studied in 69 primary immunodeficiency adult patients. Cutaquig® teaching and training was performed in the physician office setting, with dispensing and monitoring for home self-administration managed by pharmacists. The ongoing study showed good efficacy, tolerability and treatment adherence with Cutaquig®. The poster can be accessed at https://education.aaaai.org/node/26529.
Healix Clinical Outcomes Research, in collaboration with our physician partners, provides evidence-based research in areas such as drug utilization, clinical outcomes and disease response, safety, health economic impacts, and persistence. With the largest data warehouse in the outpatient infusion industry, we proudly present class-leading studies in the physician office site of care. For more information, visit our website at https://healix.net/outcomes-research/.
About Healix Infusion Therapy, LLC
Healix is the nation’s leader in providing physician office-based infusion services. Focused on patient and physician peace of mind for 30 years, we offer unparalleled capabilities for optimal patient care, comfort, compliance, and clinical outcomes in an outpatient setting.